Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
Summary
Fate Therapeutics. Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
| Authors | Ghobadi A, Bachanova V, Patel K, Park JH, Flinn I, Riedell PA, Bachier C, Diefenbach CS, Wong C, Bickers C, Wong L, Patel D, Goodridge J, Denholt M, Valamehr B, Elstrom RL, Strati P |
|---|---|
| Journal | Lancet (London, England) |
| Publication Date | 2025 Jan 11;405(10473):127-136 |
| PubMed | 39798981 |
| PubMed Central | PMC11827677 |
| DOI | 10.1016/s0140-6736(24)02462-0 |
Research Projects
Cell Lines
- (none)